Exelixis, Inc. — Form 10-Q Summary
Period: The filing covers the quarter ended July 1, 2022, presented in the statements as June 30, 2022, and the six months ended that date. The request metadata says “2021 Q2,” but the filing itself is for 2022 Q2.
Business context
Exelixis is an oncology-focused biotechnology company. CABOMETYX (cabozantinib) generated the large majority of revenue; the company also markets COMETRIQ and earns collaboration revenue from products including COTELLIC. It is investing in cabozantinib development and a broader pipeline, including XL092, XB002, XL102 and XL114.
Financial performance
Amounts below are in U.S. dollars; figures are rounded. Quarter comparisons are year over year.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $419.4m | $385.2m | $775.4m | $655.4m |
| Net product revenue | $347.0m | $284.2m | $657.3m | $511.5m |
| Operating income | $83.7m | $123.0m | $166.9m | $118.4m |
| Net income | $70.7m | $96.1m | $139.2m | $97.7m |
| Diluted earnings per share | $0.22 | $0.30 | $0.43 | $0.30 |
| Operating cash flow | Not separately presented for the quarter | $178.8m | $221.0m |
- Q2 revenue rose 9%; net product revenue rose 22%, principally on higher CABOMETYX unit sales. CABOMETYX net revenue was $339.2m, up 23%; COMETRIQ revenue was $7.9m, down 9%.
- Q2 operating expenses increased to $335.7m from $262.2m. R&D rose 34% to $199.5m and SG&A rose 25% to $122.8m. Operating income fell 32% and net income fell 26%, despite revenue growth.
- Approximate Q2 operating margin was 20.0%, versus 31.9% a year earlier; net margin was 16.9%, versus 25.0%. Gross margin was 96%, versus 95%.
- For the first half, revenue rose 18%, operating income rose 41% and net income rose 43%. Operating margin was approximately 21.5%, versus 18.1%; net margin was approximately 18.0%, versus 14.9%.
- Q2 license revenue increased 45% to $57.5m, including recognition of $25.7m tied to two cabozantinib regulatory milestones. Collaboration services revenue fell 76% to $14.9m, largely reflecting a prior-year catch-up in Ipsen development-cost reimbursements.
Liquidity, cash flow and obligations
- At June 30, cash, cash equivalents, restricted cash equivalents and investments totaled $2.01bn, up from $1.85bn at year-end 2021. Working capital was $1.55bn.
- First-half operating cash flow was $178.8m, down from $221.0m, despite higher net income. Management attributed the decrease mainly to operating expense payments and unfavorable changes in operating assets and liabilities; the period included collection of a $100m Ipsen milestone.
- First-half investing cash outflow was $209.7m, primarily reflecting net investment purchases; financing cash inflow was $4.6m. Cash, cash equivalents and restricted cash equivalents ended the period at $637.7m.
- The balance sheet reports no borrowings or financial debt. It does report substantial lease obligations: $161.0m in long-term operating lease liabilities, following commencement of a new 220,517-square-foot headquarters building lease. Management said available liquidity and expected revenue should fund operations for at least 12 months after filing.
Changes, outlook and key risks
- Management expected net product revenue for the rest of 2022 to increase year over year, while discount and allowance rates could rise. It expected collaboration services revenue to decline, and R&D and SG&A expenses to increase. The filing provides no numeric full-year revenue or earnings guidance.
- In July, Exelixis reported that the phase 3 COSMIC-313 trial met its primary progression-free-survival endpoint for the cabozantinib/nivolumab/ipilimumab combination, but the interim analysis showed no significant overall-survival benefit; the trial continues. The company planned to discuss next steps with the FDA.
- Key risks include dependence on CABOMETYX and its continued market acceptance, payer coverage and pricing pressure, clinical and regulatory uncertainty, competition, reliance on collaboration partners, and possible generic entry. MSN and Teva have filed ANDAs for generic CABOMETYX; litigation is ongoing. Exelixis warned early generic competition could materially harm U.S. product revenue, and said potential loss exposure could not be estimated.
- The company disclosed that its 340B integrity initiative was under HHS review and could face enforcement or require modification. COVID-19 was described as having a modest operational impact, while the Russo-Ukrainian War could affect trial recruitment and operations.
- Other notable items: Exelixis paid BioInvent a $25m upfront fee for an option and license arrangement; it also commenced a long-term operating lease and expanded existing office space. The filing describes potential future milestone obligations under business-development arrangements, but does not present them as currently due debt.
Investor facts to verify
- Whether CABOMETYX volume growth can offset rising discounts, rebates and payer-related pressure.
- Whether higher R&D and SG&A spending delivers pipeline and commercial progress without materially eroding profitability or operating cash flow.
- Developments and timing in the MSN and Teva patent cases, and the potential effect of any generic launch on CABOMETYX revenue.
- Clinical and regulatory follow-through for COSMIC-313 and other cabozantinib studies, plus progress and costs for XL092 and earlier-stage programs.
- Cash-flow trends, investment portfolio values and liquidity needs as lease payments, clinical spending and business-development commitments grow.